Mylan to sell two drugs to get clearance for Meda buy

(July 29, 2016) -- Drug giant Mylan has agreed to sell rights and assets related to products for treating muscle spasms and epilepsy to satisfy the government’s concerns that its $7.2 billion purchase of rival Meda would be anticompetitive....

Related Sections